Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial.

CONCLUSION: Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastuzumab pre-treated ER-positive/HER2-positive advanced breast cancer with a PAM50 luminal A or B subtype. The enrollment was stopped prematurely and a new randomized cohort was opened in this population.
PMID: 32938620 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 15, 2020 Category: Cancer & Oncology Authors: Ciruelos EM, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez de Dueñas E, Cortés J, Vázquez S, Perelló A, Garau I, Melé M, Martínez Jañez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Ve Tags: Clin Cancer Res Source Type: research